Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Roivant Sciences Ltd (NQ: ROIV ) 10.98 +0.04 (+0.37%) Streaming Delayed Price Updated: 4:00 PM EDT, May 24, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Roivant Sciences Ltd < Previous 1 2 3 4 5 6 7 Next > Vivek Ramaswamy Breathes New Life Into Beaten Down BuzzFeed Stock: What's Going On? May 22, 2024 BuzzFeed shares surged after Vivek Ramaswamy acquired a 7.7% stake for $3.2 million. Via Benzinga Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provide Business Update on Thursday, May 30, 2024 May 16, 2024 From Roivant Sciences Via GlobeNewswire Biotech Breakthroughs: 7 Stocks Driving the Next Wave in Healthcare May 07, 2024 Investors concerned about broader market undulations may want to consider the resilience narrative of these biotech stocks to buy. Via InvestorPlace 3 Healthcare Stocks With the Potential to Triple Your Investment by 2026 May 01, 2024 Learn how these three healthcare stocks offer sharp opportunities in pharmaceuticals, healthcare services, and biotechnology. Via InvestorPlace Critical Insights From Roivant Sciences Analyst Ratings: What You Need To Know April 22, 2024 Via Benzinga Where Roivant Sciences Stands With Analysts March 25, 2024 Via Benzinga The Analyst Landscape: 4 Takes On Roivant Sciences February 14, 2024 Via Benzinga Roivant Sciences Earnings Preview February 12, 2024 Via Benzinga Vivek Ramaswamy-Founded Roivant's Anti-Inflammatory Drug Aces Mid-Stage Study April 02, 2024 Roivant Sciences and Priovant Therapeutics report Phase 2 results for brepocitinib in treating non-anterior non-infectious uveitis. Week 24 data show promising efficacy, with lower treatment failure... Via Benzinga Roivant Sciences Stock Flirts With Breakout On 'Extremely Positive' Eye-Disease Study April 02, 2024 The company hopes to treat noninfectious uveitis and is rivaling AbbVie's Humira. Via Investor's Business Daily Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million April 02, 2024 From Roivant Sciences Via GlobeNewswire 10 Health Care Stocks Whale Activity In Today's Session March 29, 2024 Via Benzinga Assessing Roivant Sciences: Insights From 5 Financial Analysts January 02, 2024 Via Benzinga Analyst Ratings for Roivant Sciences December 12, 2023 Via Benzinga 8 Analysts Have This to Say About Roivant Sciences November 14, 2023 Via Benzinga Solar Stocks Rally, Led By Sunrun, SolarEdge, Enphase March 27, 2024 Solar stocks are racking up a strong day in trading, with several of the renewable energy firms up by double-digits in Wednesday trading. Via Investor's Business Daily 5 Value Stocks In The Healthcare Sector February 19, 2024 Via Benzinga Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business Update February 13, 2024 From Roivant Sciences Via GlobeNewswire Roivant to Report Financial Results for the Third Quarter Ended December 31, 2023, and Provide Business Update on Tuesday, February 13, 2024 January 30, 2024 From Roivant Sciences Via GlobeNewswire Earnings Scheduled For February 13, 2024 February 13, 2024 Companies Reporting Before The Bell • LCI Indus (NYSE:LCII) is likely to report quarterly earnings at $0.18 per share on revenue of $838.27 million. Via Benzinga Why Big Pharma Led By Merck, Sanofi, Teva Are Pouring Billions Into A New Immunology Space January 12, 2024 The companies are working on blocking TL1A, a protein tied to inflammatory bowel disease. Via Investor's Business Daily Analyst Highlights Aclaris Therapeutics' Encouraging Efficacy For Eczema Candidate, But Cautions On Data Variations January 10, 2024 Wednesday, Aclaris Therapeutics Inc (NASDAQ: ACRS) released topline results from its Phase 2b study of ATI-1777, an investigational topical "soft" JAK 1/3 inhibitor, in patients with mild to Via Benzinga Autoimmune Disease Player Immunovant's Investigational Drug For Immune System Disorder Shows Response Rates Of Over 50% December 21, 2023 Immunovant Inc (NASDAQ: IMVT), on Thursday, released the results from the initial cohort of patients in an ongoing 24-week Phase 2 trial of batoclimab in Via Benzinga Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease December 20, 2023 From Roivant Sciences Via GlobeNewswire FedEx Posts Downbeat Earnings, Joins Steelcase, argenx And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session December 20, 2023 U.S. stock futures were lower this morning, with the Dow Jones futures falling around 30 points on Wednesday. Via Benzinga Topics Stocks Exposures US Equities Roche Completes Acquisition of Telavant from Roivant, Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease December 14, 2023 From Roivant Sciences Via GlobeNewswire Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential November 28, 2023 From Roivant Sciences Via GlobeNewswire Why Is Vivek Ramaswamy-Founded Roivant Sciences Stock Trading Lower Today? November 27, 2023 Roivant Sciences Ltd (NASDAQ: ROIV) and Priovant's Phase 2 study of oral brepocitinib in moderate to severe active lupus did not meet its primary endpoint of Systemic Lupus Erythematosus (SLE) Via Benzinga Roivant and Priovant Announce Results from Phase 2 Study of Oral Brepocitinib in Systemic Lupus Erythematosus November 27, 2023 From Roivant Sciences Via GlobeNewswire Roivant Reports Financial Results for the Second Quarter Ended September 30, 2023, and Provides Business Update November 13, 2023 From Roivant Sciences Via GlobeNewswire < Previous 1 2 3 4 5 6 7 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.